Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

Alcon Research267 enrolled

Overview

The purpose of this study is to compare the effectiveness of Nepafenac Ophthalmic Suspension, 0.1% eye drops to Acular LS eye drops, used before and after cataract surgery, for treating inflammation in the eye.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

267

Conditions

Cataract

Interventions

Nepafenac Ophthalmic Suspension, 0.1%DRUG

Eligibility

Sex: ALLMin age: 10 Years

Medical Language ↔ Plain English

Inclusion Criteria: * planned cataract extraction with posterior chamber intraocular lens implantation Exclusion Criteria: * Under 10

Locations (1)

Lehmann Eye Center

Nacogdoches, Texas, United States

Outcomes

Primary Outcomes

Percentage of patients who are a clinical success at Day 14 postoperative visit (where a "clinical success" is defined as aqueous cells < grade 1 and aqueous flare = grade 0 at the current visit and all subsequent visits).

Secondary Outcomes

Percentage of patients who are clinically cured, clinical successes, treatment failure, clinically significant inflammation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.